Consistent with these observations, CD8+ T lymphocytes, which have been co-cultured with ECM-myCAF silenced for CYR61, showed an increased capacity to kill cancer cells (Supplementary Fig. S7F), suggesting that the secreted factor CYR61, a well-known YAP1-target gene, might mediate ECM-myCAF immunosuppressive activity on CD8+ T cells. The gene discussed is CD8A; the disease is cancer.